DILON Diagnostics to distribute GE's Discovery NM750b breast imaging system in North America

DILON Diagnostics and GE Healthcare are pleased to announce that they have signed an agreement for DILON to be the exclusive distributor of GE's Discovery NM750b Molecular Breast Imaging system in North America. The signing of this exclusive agreement brings closer together two significant players in Molecular Breast Imaging. Last year, GE Healthcare and DILON Diagnostics signed a global distribution agreement in select world markets.

The Discovery NM750b breast imaging system offers clinicians an important tool for imaging of a broad range of patients, including those with dense breasts who may be at higher risk for breast cancer. The power of functional imaging to see early changes is a key factor in early detection in breast cancer.

"We are very pleased to continue collaborating with GE Healthcare, a world leader in innovation, in the fight against breast cancer. The relationship with GE Healthcare will enable us to offer a complete spectrum of BSGI/MBI solutions through our established sales channels in breast cancer diagnostics and surgery," says Robert G. Moussa, DILON Diagnostics Chairman and CEO. Nathan Hermony, Nuclear Imaging global business manager for GE Healthcare, added that "GE believes strongly in this advanced technology and the potential for this type of imaging to improve breast cancer diagnosis. DILON Diagnostics will further the education and acceptance of Molecular Breast Imaging."

Source:

Dilon Technologies, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
POINT project launches video to showcase its healthcare advancements